Clinical Trial Update: Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 3]

View source ↗

Summary

Phase 3 results for sipuleucel-T (Provenge) vaccine therapy in metastatic castration-resistant prostate cancer were posted, representing pivotal trial findings …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PROVENGE (sipuleucel-T)

Snippet

Sponsor: Dendreon | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2010-11-01